Innoviva Inc. Stock
Innoviva Inc. Stock
Innoviva Inc. shows a slight decrease today, losing -€0.100 (-0.570%) compared to yesterday.
Our community is currently high on Innoviva Inc. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 24 € shows a positive potential of 37.93% compared to the current price of 17.4 € for Innoviva Inc..
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | -0.570% | -4.891% | 0.000% | -2.235% | 6.061% | 42.276% | 101.149% |
| Pacira Pharmaceuticals | -0.980% | 2.000% | 13.966% | 14.607% | 10.270% | -53.846% | -58.197% |
| Rockwell Medical Inc. | -1.480% | -0.762% | -1.969% | -58.300% | -58.011% | -14.925% | -92.025% |
| Twist Bioscience Corp | 0.360% | 0.653% | 6.119% | -44.411% | -39.318% | 15.217% | -74.541% |
Comments
Innoviva (NASDAQ:INVA) had its price target raised by analysts at Cantor Fitzgerald from $29.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva (INVA) Q2 Sales Jump 64%
Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share
